Different lymphoid cell populations produce varied levels of neopterin, β2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha
Open Access
- 28 June 1992
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 88 (3) , 548-554
- https://doi.org/10.1111/j.1365-2249.1992.tb06485.x
Abstract
Immune activation is central to many immune disorders. Clinical investigations have shown that immune activation can be quantified by measurements of soluble immune activation products in serum. Most in vitro studies of these immune activation products have focused on single products. In this study the specific cell sources and the major lymphokines inducing multiple activation products were investigated. In vitro addition of interferon‐gamma (IFN‐γ) or IL‐2 stimulated peripheral blood mononuclear cells to produce neopterin, β2‐microglobulin (β‐M) and soluble IL‐2 receptor (sIL‐2R). These two lymphokines can act independently, because neutralizing antibodies to one of the lymphokines did not block the inducing activity of the other. Tumour necrosis factor‐alpha (TNF‐α) was also investigated and shown to be a less powerful inducer than IL‐2 or INF‐γ. Separated lymphoid subpopulations responded differently to specific lymphokines. Monocytes produced only neopterin and only in response to INF‐γ. T cells released β2‐M and sIL‐2R in response to IL‐2. B cells, however, were capable of producing all three immune activation products. Neopterin production in B cells was induced by either INF‐γ of IL‐2, indicating that B cells have additional mechanisms for responding to lymphokines. To investigate whether these in vitro findings also occur in vivo, sera from patients who had received either rIL‐2 or INF‐γ treatment were tested. INF‐γ administration led to substantial increases in serum neopterin but only a moderate β2‐M increase and no increase in the serum sIL‐2R levels. rIL‐2 administration caused a substantial increase of all three serum immune activation products, consistent with our in vitro findings. The results confirm that increased serum levels of soluble immune activation products are indicators of increased cytokine production by lymphocytes and monocytes and also that B cells can be a prominent source of immune activation products.Keywords
This publication has 34 references indexed in Scilit:
- Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV infection: Distinctive parameters of HIV-induced changeClinical Immunology and Immunopathology, 1991
- Serum beta2-microglobulin level increases in HIV infectionAIDS, 1990
- The Prognostic Value of Cellular and Serologic Markers in Infection with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1990
- Neopterin as a marker for activated cell-mediated immunity: Application in HIV infectionImmunology Today, 1988
- In vitro activation of T lymphocytes from human immunodeficiency virus (HIV)-seropositive blood donors. I. Soluble interleukin 2 receptor (IL2R) production parallels cellular IL2R expression and DNA synthesisJournal of Clinical Immunology, 1988
- Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.The Journal of Experimental Medicine, 1984
- β‐MICROGLOBULIN SERUM LEVELS IN INFECTIOUS MONONUCLEOSIS IN CHILDHOODActa Pathologica Microbiologica Scandinavica Section C Immunology, 1981
- β2‐Microglobulin in Chronic Lymphocytic LeukaemiaScandinavian Journal of Haematology, 1980
- Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas findings in a multicenter study and experience in selected patientsCancer, 1980
- Plasma and urinary levels of beta2 microglobulin in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1978